SELLAS Life Sciences (SLS) Long-Term Debt Issuances (2016 - 2017)
SELLAS Life Sciences (SLS) reported Long-Term Debt Issuances of -$4.4 million for Q2 2017, down 118.82% year-over-year from $23.6 million in Q2 2016, and down 200.0% quarter-over-quarter from $4.4 million in Q1 2017.
SELLAS Life Sciences (SLS) Long-Term Debt Issuances (2016 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has 2 years of Long-Term Debt Issuances data on file, last reported at -$4.4 million in Q2 2017.
- Long-Term Debt Issuances for Q2 2017 came in at -$4.4 million, down 118.82% year-over-year; the trailing twelve-month figure through Sep 2017 was -$8.6 million (down 136.55% YoY), and the FY2016 annual result was $15.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances eased to -$4.4 million in Q2 2017 per SLS's latest filing, from $4.4 million in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $23.6 million in Q2 2016 and troughed at -$8.6 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -4.45 Mn |
| Jun 30, 2017 | -4.45 Mn |
| Mar 31, 2017 | 4.45 Mn |
| Mar 31, 2017 | 4.45 Mn |
| Dec 31, 2016 | -8.64 Mn |
| Dec 31, 2016 | -8.64 Mn |
| Jun 30, 2016 | 23.64 Mn |
| Jun 30, 2016 | 23.64 Mn |